is tirzepatide coming off the market FDA says this weight loss drug shortage over, but patients worry about cost and availability FDA Approves Tirzepatide, A Potential

But Wegovy may increase the risk of pancreatitis, gallbladder disease, severe gastrointestinal side effects that may lead to dehydration or kidney injury, increased heart rate, and suicidal thoughts or behaviors

Epub 2016 Oct 3

Genetic Predispositions in GLP-1 Pathway Function and Response Variability Genetic variation in GLP-1 receptor signaling, glucose-sensing pathways, and appetite regulation influences individual treatment response

The researchers said previous research had shown that patients who took tirzepatide had a decline in high-sensitivity CRP levels

Both tirzepatide and semaglutide are injectable medications designed to help with weight loss